SUMMARY BackgroundCurrently, although only a few therapies normalize the liver test abnormalities with ⁄ without improving the liver histology, no pharmacologic therapy has proved to be effective for the treatment of non-alcoholic steatohepatitis.

No abstract

No abstract

Amaç: Kronik karaci¤er hastal›¤› olan olgularda karaci¤er dokusundaki fibrozis varl›¤›n›n ve miktar›n›n de¤erlendirilmesi; tedavi stratejisini, tedaviye yan›t› ve prognozu belirleyen en önemli etkendir. Bu çal›flman›n amac› karaci¤er fibrozisinin de¤erlendiril-mesinde proteomik analiz ile yeni biyolojik belirteçlerin araflt›r›lmas›d›r. Yöntem: Kronik karaci¤er hastal›¤› olan toplam 87 hasta (Metavir indeks ile, 17 F0, 30 F1, 6 F2, 9 F3 ve 21 F4) (using METAVIR index, 17 F0, 30 F1, 6 F2, 9 F3, and 21 F4 patients)

Secondary amyloidosis (AA amyloidosis) has rarely been described in patients with systemic lupus erythematosus (SLE). We, herein, present a 56-year-old female patient, who developed AA amyloidosis following a 22-year history of SLE. She developed severe mitral regurgitation complicated with chordae tendinea rupture that led to acute congestive heart failure and went on a mitral valve replacement, where no flare symptoms of SLE were present. Three months after the operation, she presented with a nephrotic-range proteinuria, acute renal failure, and severe sepsis. She was found to have new vegetations on replaced valve and multi-organ failure caused her death. Re-evaluation of the excised mitral valve revealed AA amyloid deposition. Post-mortem biopsies from the kidney and bone marrow also revealed secondary amyloidosis.